Inhibition of BCR Signaling Using the Syk Inhibitor TAK-659 Prevents Stroma-Mediated Signaling in Chronic Lymphocytic Leukemia Cells

Autor/a

Purroy, Noelia

Carabia, Júlia

Abrisqueta, Pau

Egia-Mendikute, Leire

Aguiló, Meritxell

Carpio, Cecilia

Palacio, Carles

Crespo, Marta

Bosch, Francesc

Data de publicació

2020-12-16T11:45:15Z

2020-12-16T11:45:15Z

2017-01-03

2020-12-16T11:45:15Z



Resum

Proliferation and survival of chronic lymphocytic leukemia (CLL) cells depend on microenvironmental signals coming from lymphoid organs. One of the key players involved in the crosstalk between CLL cells and the microenvironment is the B-cell receptor (BCR). Syk protein, a tyrosine kinase essential for BCR signaling, is therefore a rational candidate for targeted therapy in CLL. Against this background, we tested the efficacy of the highly specific Syk inhibitor TAK-659 in suppressing the favorable signaling derived from the microenvironment. To ex vivo mimic the microenvironment found in the proliferation centers, we co-cultured primary CLL cells with BM stromal cells (BMSC), CD40L and CpG ODN along with BCR stimulation. In this setting, TAK-659 inhibited the microenvironment-induced activation of Syk and downstream signaling molecules, without inhibiting the protein homologue ZAP-70 in T cells. Importantly, the pro-survival, proliferative, chemoresistant and activation effects promoted by the microenvironment were abrogated by TAK-659, which furthermore blocked CLL cell migration toward BMSC, CXCL12, and CXCL13. Combination of TAK-659 with other BCR inhibitors showed synergistic effect in inducing apoptosis, and the sequential addition of TAK-659 in ibrutinib-treated CLL cells induced significantly higher cytotoxicity. These findings provide a strong rationale for the clinical development of TAK-659 in CLL.


This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI 11/00792, PI14/00055, F.B and PI13/00279, M.C), cofinanced by the European Regional Development Fund (ERDF) and Asociación Española Contra el Cáncer (AECC, M.C). N.P. is a recipient of a PhD fellowship granted by Institut de Recerca Vall d’Hebron. C.C. is supported by a grant from Sociedad Española de Hematología y Hemoterapia (SEHH). M.C. holds a contract from Ministerio de Economía y Competitividad (MINECO) (RYC-2012-12018).

Tipus de document

Article
Versió publicada

Llengua

Anglès

Matèries i paraules clau

CLL; Syk; Microenvironment; TAK-659; BCR inhibitor

Publicat per

Impact Journals

Documents relacionats

info:eu-repo/grantAgreement/MINECO//RYC-2012-12018/ES/RYC-2012-12018/

Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.13557

Oncotarget, 2017, vol. 8, num. 1, p. 742-756

Drets

cc-by (c) Purroy, Noelia et al., 2017

http://creativecommons.org/licenses/by/3.0/es

Aquest element apareix en la col·lecció o col·leccions següent(s)